A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-12

Study Completion Date

2024-02-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to evaluate the response of glucagon to insulin-induced low blood sugar after administration of the study drug LY3532226 in participants with type 1 diabetes mellitus (T1DM). The study will also evaluate if LY3532226 helped participants to recover from insulin-induced low blood sugar condition compared to placebo. The study will last approximately 16 weeks excluding screening period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus

NCT05407961

Diabetes Mellitus, Type 2

COMPLETED PHASE1

Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose

NCT01300260

Diabetes Mellitus, Type 2

COMPLETED PHASE1

Liraglutide in the Treatment of Type 1 Diabetes Mellitus

NCT01722266

Type 1 Diabetes

COMPLETED PHASE3

Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes

NCT01722227

Type 1 Diabetes

WITHDRAWN PHASE3

A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

NCT05377333

Diabetes Mellitus, Type 2

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3532226

Group Type EXPERIMENTAL

LY3532226

Intervention Type DRUG

Administered subcutaneously (SC).

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered SC.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3532226

Administered subcutaneously (SC).

Intervention Type DRUG

Placebo

Administered SC.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants with type 1 diabetes mellitus (T1DM) for at least 2 years treated with insulin
* Body mass index (BMI) of 18.5 to 40.0 kilograms per meter squared (kg/m²)
* Are males or females not of childbearing potential

Exclusion Criteria

* Have acute proliferative retinopathy requiring active treatment within 3 months of screening
* Have been treated with dipeptidyl peptidase-Ni, GLP-1 receptor agonists, GIP agonists, metformin or sodium-glucose cotransporter 2 inhibitors within the previous 3 months
* Have received systemic or inhaled glucocorticoid therapy
* Women of childbearing potential
* Are currently taking part in another clinical study trial involving medical research, or have participated within the last 30 days of screening in a clinical study involving a study intervention

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No